Stay updated with breaking news from Clinical Study Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cosentyx® is the first new biologic treatment for hidradenitis suppurativa in nearly a decade, offering clinically meaningful results across the most debilitating... | June 1, 2023
Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa • Positive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly a decade • Committee for Medicinal Products for Human Use (CHMP) opinion based...
Positive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly a decade Committee for Medicinal Products for Human Use (CHMP) opinion based on robust Phase
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa
Positive opinion paves way for first new treatment option in hidradenitis suppurativa in nearly a decade Committee for Medicinal Products for Human Use opinion based on robust Phase III data... | April 26, 2023